3 years 4.81
Extreme 4.814997
31.5
5 years 4.81
Extreme 4.814997
64.5
10 years 4.81
Extreme 4.814997
450
Manager TitleAgeSince
Chief Executive Officer 67 2025-05-20
Chief Tech/Sci/R&D Officer - 2019-12-31
Investor Relations Contact - 2020-07-31
Director TitleAgeSince
Director/Board Member 67 2025-05-20
Date Insider Type Main position Quantity % Market Cap. Importance
5/21/25 Issuer sale

Chief Financial Officer

82,491 0.8204%
5/21/25 Issuer sale

Director

12,624 0.1255%
5/21/25 Issuer sale

Director

12,624 0.1255%
Change 5-day change 1-year change 3-year change Capi.($)
-1.13%-.--% - - 97.22M
+0.83%+3.19%+41.49%+103.56% 1,051B
+1.93%+2.11%+37.08%+65.09% 630B
+1.49%+5.19%+19.94%+85.69% 489B
+2.26%+0.90%+69.32%+40.53% 359B
+1.45%+3.50%+23.29%+41.62% 344B
+1.17%+2.37%+13.47%+33.64% 272B
+0.89%+1.08%-6.13%+9.29% 246B
+1.82%+2.94%+42.99%+52.95% 224B
+2.77%+4.44%+29.01%+98.99% 187B
Average +1.35%+2.53%+30.05%+59.04% 422.63B
Weighted average by Cap. +1.47%+2.44%+33.36%+69.01%
Logo OPTINOSEPAR
OptiNose, Inc. is a specialty pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. It has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.
Employees
128
  1. Stock Market
  2. Stocks
  3. OPTN Stock